Prudential PLC Boosts Bristol Myers Squibb Stake

Institutional investor increases holdings in biopharmaceutical company by 8.5%

Mar. 14, 2026 at 10:18am

Got story updates? Submit your updates here. ›

Prudential PLC, a major institutional investor, has increased its stake in Bristol Myers Squibb Company by 8.5% in the third quarter, according to a recent 13F filing with the Securities & Exchange Commission. Prudential now owns 463,306 shares of the biopharmaceutical company's stock, worth approximately $20.9 million.

Why it matters

This move by Prudential PLC suggests confidence in Bristol Myers Squibb's long-term prospects, as the company continues to advance its pipeline of cancer and immune-mediated therapies. Institutional investor activity can provide valuable insights into market sentiment around a stock.

The details

According to the 13F filing, Prudential PLC acquired an additional 36,159 shares of Bristol Myers Squibb during the third quarter, increasing its total holdings by 8.5%. The firm now owns 463,306 shares of the biopharmaceutical company's stock, valued at $20.9 million as of the most recent SEC reporting period.

  • Prudential PLC increased its Bristol Myers Squibb holdings in the third quarter of 2026.

The players

Prudential PLC

A major institutional investor and financial services group headquartered in the United Kingdom.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, with a strong emphasis on cancer and immune-mediated conditions.

Got photos? Submit your photos here. ›

The takeaway

Prudential PLC's increased stake in Bristol Myers Squibb suggests the institutional investor sees long-term value in the biopharmaceutical company's pipeline and growth prospects, even as the broader market sentiment remains mixed according to analyst ratings.